5 enrolling by invitation. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Enrolling by invitation 5 |
| Phase 3 | 2 | Enrolling by invitation 2 |
Follow Dwarfism: new trials by email Literature Review of Dwarfism trials Research Report on Dwarfism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia Infigratinib - Hypochondroplasia | Phase 2 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 135 | 2026-04-23 | 2026-08-26 |
| An Interventional Study of Infigratinib in Children With Hypochondroplasia infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day - Hypochondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 24 | 2025-04-22 | 2026-07-16 |
| A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) LUM-201 - Growth Hormone Deficiency | Phase 2 | Enrolling by invitation | Lumos Pharma | 60 | 2023-08-01 | 2024-02-15 |
| A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia TransCon CNP - Achondroplasia | Phase 2 / Phase 3 | Enrolling by invitation | Ascendis Pharma Growth Disorders A/S | 140 | 2023-06-21 | 2026-08-17 |
| Extension Study of Infigratinib in Children With Achondroplasia (ACH) Infigratinib - Achondroplasia | Phase 2 | Enrolling by invitation | QED Therapeutics, a BridgeBio company | 325 | 2021-12-06 | 2026-10-26 |
Bone Diseases (3) · Genetic Diseases, Inborn (3) · Mucopolysaccharidosis IV (3) · Musculoskeletal Diseases (3) · Osteochondrodysplasias (3) · Achondroplasia (2) · Hypochondroplasia (2) · Dwarfism, Pituitary (1)
Bone Diseases, Developmental (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Endocrine System Diseases (4) · Carbohydrate Metabolism, Inborn Errors (3) · Connective Tissue Diseases (3) · Lysosomal Storage Diseases (3) · Metabolic Diseases (3) · Metabolism, Inborn Errors (3) · Mucinoses (3) · Mucopolysaccharidoses (3) · Nutritional and Metabolic Diseases (3) · Skin and Connective Tissue Diseases (3) · Bone Diseases (2) · Musculoskeletal Diseases (2)
infigratinib (3)
QED Therapeutics, a BridgeBio company (3) · Ascendis Pharma Growth Disorders A/S (1) · Lumos Pharma (1)
Australia (5) · United States (5) · Canada (4) · France (4) · Spain (4) · United Kingdom (4) · Norway (3) · Portugal (3) · Singapore (3) · Sweden (2) · Argentina (1) · Austria (1) · Denmark (1) · Germany (1) · Ireland (1)